Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis
Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion, in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Peritonitis.
Sponsor: Yuria-Pharm
Listed as NCT03771170, this PHASE4 trial focuses on Intoxication and Peritonitis and remains completed. Sponsored by Yuria-Pharm, it has been updated 9 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Feb 2020 — Mar 2020 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE4
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE4
-
Jan 2019 — Nov 2019 [monthly]
Recruiting PHASE4
First recorded
Jan 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Yuria-Pharm
For direct contact, visit the study record on ClinicalTrials.gov .